New findings from the bipolar collaborative network: Clinical implications for therapeutics

Current Psychiatry Reports

Volumn 8, Issue 6, 2006, Pages 489-497

  Post, Robert M ^a,b   Altshuler, Lori L ^c   Frye, Mark A ^c   Suppes, Trisha ^d   McElroy, Susan ^e   Keck Jr , Paul E ^e   Leverich, Gabriele S ^f   Kupka, Ralph ^g   Nolen, Willem A ^g   Grunze, Heinz ^h  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Bipolar Collaborative Network   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; MODAFINIL; MOOD STABILIZER; PLACEBO; SERTRALINE; SIBUTRAMINE; TOPIRAMATE; TRANYLCYPROMINE; VALPROIC ACID; VENLAFAXINE; ZONISAMIDE;

ADD ON THERAPY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; CHILDHOOD; CLINICAL TRIAL; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPOMANIA; MOOD DISORDER; OBESITY; ONSET AGE; OVARY POLYCYSTIC DISEASE; PROGNOSIS; RAPID CYCLING BIPOLAR DISORDER; REVIEW; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ADULT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; CHILD; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS, DIFFERENTIAL; HUMANS; PROGNOSIS;

EID: 33845892528     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-006-0056-5     Document Type: Review

References (42)

1. Post RM, Leverich GS, Altshuler LL, et al.: An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar Disord 2003, 5:310-319.
2. Post RM, Altshuler LL, Frye MS, et al.: An overview of recent findings of the Stanley Foundation Bipolar Network (SFBN) (Part II): focus on anticonvulsants. Aspects Affect 2005, 1:8-17.
3. Suppes T, Mintz J, McElroy SL, et al.: Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network: a sex-specific phenomenon. Arch Gen Psychiatry 2005, 62:1089-1096.
4. Kraepelin E: Manic-Depressive Insanity and Paranoia. Edited by Robertson GM, Barclay RM (translator). Edinburgh, Scotland: E. S. Livingstone; 1921.
5. Frye MA, Altshuler LL, McElroy SL, et al.: Gender differences in prevalence, risk, and clinical correlates of alcoholism comorbidity in bipolar disorder. Am J Psychiatry 2003, 160:883-889.
6. Vieta E: Bipolar mixed states and their treatment. Expert Rev Neurother 2005, 5:63-68.
7. Rasgon NL, Altshuler LL, Fairbanks L, et al.: Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005, 7:246-259.
8. Kupka RW, Luckenbaugh DA, Post RM, et al.: Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry 2005, 162:1273-1280.
9. Post RM, Denicoff KD, Leverich GS, et al.: Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH Life Chart Method. J Clin Psychiatry 2003, 64:680-690.
10. Nolen WA, Luckenbaugh DA, Altshuler LL, et al.: Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network. Am J Psychiatry 2004, 161:1447-1454.
11. Judd LL, Akiskal HS, Schettler PJ, et al.: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002, 59:530-537.
12. Judd LL, Akiskal HS, Schettler PJ, et al.: A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003, 60:261-269.
13. Denicoff KD, Leverich GS, Nolen WA, et al.: Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM-p) for longitudinal assessment of bipolar illness. Psychol Med 2000, 30:1391-1397.
14. Altshuler LL, Post RM, Black DO, et al.: Subsyndronal symptoms and functional impairment in patients wth bipolar disorder. J Clin Psychiatry 2006, In press.
15. Perlis RH, Miyahara S, Marangell LB, et al.: Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2004, 55:875-881.
16. Leverich GS, Post RM: Course of bipolar illness after history of childhood trauma. Lancet 2006, 367:1040-1042.
17. Leverich GS, Post RM: The poor prognosis of childhood-onset bipolar disorder: the need for earlier recognition and treatment. J Pediatrics 2006, In press.
18. Post RM, Kowatch RA: The health care crisis of childhood onset bipolar illness: some recommendations for its amelioration. J Clin Psychiatry 2006, 67:115-125.
19. Wang PS, Berglund P, Olfson M, et al.: Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:603-613.
20. Leverich GS, Altshuler LL, Frye MA, et al.: Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006, 163:232-239.
21. Post RM, Altshuler LL, Leverich GS, et al.: Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006, 189:124-131.
22. Nierenberg AA, Ostacher MJ, Calabrese JR, et al.: Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006, 163:210-216.
23. Altshuler LL, Suppes T, Black DO, et al.: Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry 2006, 163:313-315.
24. Benazzi F, Akiskal HS: Psychometric delineation of the most discriminant symptoms of depressive mixed states. Psychiatry Res 2006, 141:81-88.
25. Nolen WA, Kupka RW, Hellemann G, et al.: Tranylcypromine versus lamotrigne as adjunctive treatment to a mood stabilizer in bipolar depression: an open randomized controlled study. Acta Psychiatr Scand 2006, In press.
26. Himmelhoch JM, Thase ME, Mallinger AG, Houck P: Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991, 148:910-916.
27. Calabrese JR, Keck PE, Jr, Macfadden W, et al.: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005, 162:1351-1360.
28. Davis LL, Bartolucci A, Petty F: Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005, 85:259-266.
29. Zhang ZJ, Kang WH, Tan QR, et al.: Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study. J Psychiatr Res 2005. [Epub ahead of print.]
30. Altshuler L, Suppes T, Black D, et al.: Impact of anti-depressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003, 160:1252-1262.
31. Altshuler L, Kiriakos L, Calcagno J, et al.: The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. J Clin Psychiatry 2001, 62:612-616.
32. Joffe RT, MacQueen GM, Marriott M, Young LT: One-year outcome with antidepressant - treatment of bipolar depression. Acta Psychiatr Scand 2005, 112:105-109.
33. Ghaemi SN, El-Mallakh RS, Baldassano CF, et al.: A randomized clinical trial of efficacy and safety of long-term antidepressant use in bipolar disorder. Bipolar Disord 2006, 7:59.
34. Calabrese JR, Shelton MD, Rapport DJ, et al.: A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005, 162:2152-2161.
35. Frye MA, Ketter TA, Leverich GS, et al.: The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000, 61:9-15.
36. Judd LL, Akiskal HS: Depressive episodes and symptoms dominate the longitudinal course of bipolar disorder. Curr Psychiatry Rep 2003, 5:417-418.
37. Judd LL, Paulus MJ, Schettler PJ, et al.: Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000, 157:1501-1504.
38. Marangell LB: The importance of subsyndromal symptoms in bipolar disorder. J Clin Psychiatry 2004, 65:24-27.
39. McElroy SL, Frye MA, Suppes T, et al.: Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002, 63:207-213.
40. McElroy SL, Suppes T, Keck PE, Jr, et al.: Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. J Clin Psychiatry 2005, 66:617-624.
41. McElroy SL, Frye MA, Altshuler LL, et al.: A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord 2006, In press.
42. Post RM, Speer AM, Leverich GS: Bipolar illness: Which critical treatment issues need studying? Clin Approaches Bipolar Disord 2003, 2:24-30.